Plus Therapeutics (PSTV) 10-Q 11 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'CYTORI THERAPEUTICS, INC.	'
Entity Central Index Key	'0001095981	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	79,541,775
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'

CONSOLIDATED_CONDENSED_BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$12,760,000	$15,506,000
Accounts receivable, net of reserves of $1,162,000 and $1,445,000 in 2014 and 2013, respectively	2,004,000	4,152,000
Inventories, net	4,488,000	3,694,000
Other current assets	1,288,000	1,225,000
Total current assets	20,540,000	24,577,000
Property and equipment, net	1,290,000	1,054,000
Restricted cash and cash equivalents	350,000	350,000
Other assets	2,567,000	2,812,000
Intangibles, net	9,581,000	9,345,000
Goodwill	3,922,000	3,922,000
Total assets	38,250,000	42,060,000
Current liabilities:	'	'
Accounts payable and accrued expenses	6,527,000	6,077,000
Current portion of long-term obligations, net of discount	7,342,000	3,191,000
Termination fee obligation	0	400,000
Puregraft divestiture obligation	215,000	547,000
Joint Venture purchase obligation	2,647,000	4,691,000
Total current liabilities	16,731,000	14,906,000
Deferred revenues	212,000	212,000
Long-term deferred rent and other	613,000	710,000
Long-term obligations, net of discount, less current portion	19,501,000	23,100,000
Total liabilities	37,057,000	38,928,000
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2014 and 2013	0	0
Common stock, $0.001 par value; 145,000,000 shares authorized; 79,541,775 and 71,305,375 shares issued and outstanding in 2014 and 2013, respectively	79,000	71,000
Additional paid-in capital	323,848,000	303,710,000
Accumulated other comprehensive income	399,000	256,000
Accumulated deficit	-323,133,000	-300,905,000
Total stockholders' equity	1,193,000	3,132,000
Total liabilities and stockholders' equity	$38,250,000	$42,060,000

CONSOLIDATED_CONDENSED_BALANCE1

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Accounts receivable, reserves	$1,162,000	$1,445,000
Stockholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	145,000,000	145,000,000
Common stock, shares issued (in shares)	79,541,775	71,305,375
Common stock, shares outstanding (in shares)	79,541,775	71,305,375

CONSOLIDATED_CONDENSED_STATEME

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) [Abstract]	'	'	'	'
Product revenues	$935,000	$1,408,000	$1,965,000	$2,800,000
Cost of product revenues	766,000	608,000	1,187,000	1,365,000
Gross profit	169,000	800,000	778,000	1,435,000
Development revenues:	'	'	'	'
Development, related party	0	0	0	638,000
Development revenue	0	0	0	1,179,000
Government contracts and other	356,000	859,000	759,000	1,408,000
Total development revenues	356,000	859,000	759,000	3,225,000
Operating expenses:	'	'	'	'
Research and development	4,674,000	4,150,000	8,966,000	7,869,000
Sales and marketing	1,934,000	2,410,000	3,861,000	4,667,000
General and administrative	4,602,000	4,046,000	8,942,000	7,892,000
Change in fair value of warrant liability	0	-84,000	0	-418,000
Change in fair value of option liability	0	-2,500,000	0	-2,250,000
Total operating expenses	11,210,000	8,022,000	21,769,000	17,760,000
Operating loss	-10,685,000	-6,363,000	-20,232,000	-13,100,000
Other income (expense):	'	'	'	'
Loss on asset disposal	-1,000	-257,000	-1,000	-257,000
Gain on previously held equity interest in Joint Venture	0	4,892,000	0	4,892,000
Loss on debt extinguishment	0	-708,000	0	-708,000
Interest income	1,000	1,000	3,000	1,000
Interest expense	-1,085,000	-652,000	-2,026,000	-1,361,000
Other income (expense), net	-58,000	-124,000	28,000	-296,000
Equity loss from investment in joint venture	0	0	0	-48,000
Total other income (expense)	-1,143,000	3,152,000	-1,996,000	2,223,000
Net loss	-11,828,000	-3,211,000	-22,228,000	-10,877,000
Other comprehensive income (loss) foreign currency translation adjustments	193,000	76,000	143,000	-34,000
Net comprehensive loss	($11,635,000)	($3,135,000)	($22,085,000)	($10,911,000)
Basic and diluted net loss per common share (in dollars per share)	($0.15)	($0.05)	($0.29)	($0.16)
Basic and diluted weighted average common shares (in shares)	76,682,643	67,200,588	75,399,647	67,096,348

CONSOLIDATED_CONDENSED_STATEME1

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($22,228,000)	($10,877,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	344,000	660,000
Amortization of deferred financing costs and debt discount	562,000	330,000
Joint Venture acquisition obligation accretion	145,000	51,000
Provision for doubtful accounts	836,000	188,000
Provision for expired enzyme	209,000	0
Change in fair value of warrant liability	0	-418,000
Change in fair value of option liability	0	-2,250,000
Share-based compensation expense	1,448,000	1,838,000
Equity loss from investment in joint venture	0	48,000
Loss on asset disposal	0	257,000
Gain on previously held equity interest in Joint Venture	0	-4,892,000
Loss on debt extinguishment	0	708,000
Increases (decreases) in cash caused by changes in operating assets and liabilities:	'	'
Accounts receivable	1,386,000	862,000
Inventories	-526,000	-816,000
Other current assets	-59,000	-27,000
Other assets	-281,000	-587,000
Accounts payable and accrued expenses	124,000	-279,000
Deferred revenues, related party	0	-638,000
Deferred revenues	0	-1,200,000
Long-term deferred rent	-97,000	28,000
Net cash used in operating activities	-18,137,000	-17,014,000
Cash flows from investing activities:	'	'
Purchases of property and equipment	-467,000	-432,000
Expenditures for intellectual property	-255,000	0
License agreement termination fee	-400,000	-400,000
Cash acquired in purchase of the Joint Venture	0	5,000
Net cash provided by investing activities	-1,122,000	-827,000
Cash flows from financing activities:	'	'
Principal payments on long-term obligations	0	-22,292,000
Proceeds from long-term obligations	0	27,000,000
Debt issuance costs and loan fees	0	-1,744,000
Joint Venture purchase payments	-2,189,000	-70,000
Proceeds from exercise of employee stock options and warrants	33,000	115,000
Proceeds from sale of common stock	19,075,000	3,001,000
Costs from sale of common stock	-410,000	-184,000
Net cash provided by financing activities	16,509,000	5,826,000
Effect of exchange rate changes on cash and cash equivalents	4,000	-81,000
Net decrease in cash and cash equivalents	-2,746,000	-12,096,000
Cash and cash equivalents at beginning of period	15,506,000	25,717,000
Cash and cash equivalents at end of period	12,760,000	13,621,000
Cash paid during period for:	'	'
Interest	1,318,000	1,151,000
Supplemental schedule of non-cash investing and financing activities:	'	'
Fair value of warrants allocated to additional paid-in capital	0	949,000
Fair value of intangible assets acquired	0	9,394,000
Fair value of tangible assets acquired	0	260,000
Joint venture purchase obligation	0	4,709,000
Fair value of previously held equity interest at acquisition date	$0	$4,929,000

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Basis of Presentation [Abstract]	'
Basis of Presentation	'
	1	Basis of Presentation
	Our accompanying unaudited consolidated condensed financial statements as of June 30, 2014 and for the three and six months ended June 30, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.  Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.  Our consolidated condensed balance sheet at June 30, 2014 has been derived from the audited financial statements at December 31, 2013, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included.  Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.  These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2013.

Use_of_Estimates

Use of Estimates	6 Months Ended
	Jun. 30, 2014
Use of Estimates [Abstract]	'
Use of Estimates	'
	2	Use of Estimates
	The preparation of Consolidated Condensed Financial Statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.  Our most significant estimates and critical accounting policies involve recognizing revenue, determining the assumptions used in measuring share-based compensation expense and valuing allowances for doubtful accounts and inventories.
	Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the Consolidated Condensed Financial Statements in the periods they are determined to be necessary.

Capital_Availability

Capital Availability	6 Months Ended
	Jun. 30, 2014
Capital Availability [Abstract]	'
Capital Availability	'
	3	Capital Availability
	We incurred net losses of $11,828,000 and $22,228,000 for the three and six months ended June 30, 2014 and $3,211,000 and $10,877,000 for the three and six months ended June 30, 2013, respectively.  We have an accumulated deficit of $323,133,000 as of June 30, 2014.  Additionally, we have used net cash of $18,137,000 and $17,014,000 to fund our operating activities for the six months ended June 30, 2014 and 2013, respectively. To date, these operating losses have been funded primarily from outside sources of invested capital.
	We have been placing, and will continue to place, significant effort into raising additional capital that will provide adequate capital resources to allow us to continue to fund our future operations.   Based on our cash and cash equivalents on hand of $12,760,000 at June 30, 2014 and our minimum liquidity requirements of the Loan Agreement that require us to make principal and interest payments of $868,000 per month beginning in August 2014 and maintain at least three months of cash on hand, we must raise additional capital in August 2014 to avoid an event of default by August 31, 2014.   If we are unable to raise additional capital as planned, we will not have sufficient cash on hand to avoid an event of default under the Loan Agreement, which, absent a waiver or modification of the loan terms, would allow the lender to cause the loan amount of $28,670,000 to be immediately due and payable.  Our financing plans include pursuing additional cash through strategic corporate partnerships and engaging in future sales of equity, as well as obtaining a modification of the terms of the Loan Agreement. While we have an established history of raising capital through these platforms, and we are currently involved in negotiations with multiple parties, there is no guarantee that adequate funds will be available when needed from additional debt or equity financing, development and commercialization partnerships or from other sources, or on terms acceptable to us.  There is also no guarantee that our lender would agree to a modification of the Loan Agreement, or on terms that are acceptable to us.  If our efforts to obtain sufficient additional funds are not successful, in addition to the lender’s ability to cause the loan amount to be immediately due and payable, we would also be required to delay, scale back, or eliminate some or all of our research or product development, manufacturing operations, administrative operations, including our employee base, and clinical or regulatory activities, which could negatively affect our ability to achieve certain corporate goals.
	The Company continues to seek additional capital through product revenues, strategic transactions, including extension opportunities under the awarded BARDA contract, and from other financing alternatives.

Transactions_with_Olympus_Corp

Transactions with Olympus Corporation	6 Months Ended
	Jun. 30, 2014
Transactions with Olympus Corporation [Abstract]	'
Transactions with Olympus Corporation	'
	4	Transactions with Olympus Corporation
	Acquisition of Olympus’ Interest in the Joint Venture
	In 2005, we entered into a joint venture and other related agreements (the “Joint Venture Agreements”) with Olympus.  The Joint Venture was owned equally by Olympus and us.  We had previously accounted for our interests in the Joint Venture using the equity method of accounting, since we could not exert significant influence over the Joint Venture’s operations.
	On May 8, 2013, Cytori and Olympus agreed to terminate the Olympus-Cytori Joint Venture (the “Termination Agreement”), and Cytori acquired the remaining 50% equity interest in the Joint Venture from Olympus.  The termination of the relationship and purchase of the Olympus’ equity shares of the Joint Venture allows Cytori to regain full control of the manufacturing rights for the Celution ® system.  The purpose of the acquisition is to gain more flexibility on the manufacturing process and associated costs, enable higher margins, and speed the transition to the critical next-generation systems. In connection with the Termination Agreement, the assets acquired, liabilities assumed, and the Company’s previously held equity interest were recorded at fair value.  For valuation purposes Cytori determined the acquisition date (the date on which Cytori effectively gained full control of the equity interest previously held by Olympus) to be May 27, 2013.  The remeasurement of the previously held equity interest at the acquisition date resulted in a net gain of $4,892,000 that was recorded in the accompanying consolidated condensed statements of operations.
	As consideration for the Termination Agreement, Cytori can choose from alternative payment options as defined in the Termination Agreement.  The payment options call for a minimum of $4,500,000 up to a maximum of $16,000,000 to be paid by Cytori to Olympus in installments over periods ranging from one year to six years depending on the option selected by the Company.  Installment payments will be calculated quarterly based on 5% of Cytori’s gross sales receipts for all products sold.  If Cytori receives an aggregate $35,000,000 in cash through strategic or financing arrangements during the first year of the Termination Agreement, Cytori will pay $4,500,000 upon request of Olympus as full and complete consideration under the Agreement.
	The fair value of the Joint Venture, including the identified intangible assets acquired, consideration transferred, and Cytori’s previously held equity interest, was estimated from a market participant perspective, using valuation techniques based on the income approach for measuring fair value.  Specifically, an excess earnings methodology was employed using primarily Level 3 fair value inputs.  The intangible assets acquired consisted primarily of contractual license rights that had previously enabled the Joint Venture to conduct development and manufacturing activities pertaining to certain aspects of Cytori’s Celution ® technology.  The useful life of the identifiable intangible assets was estimated based on the assumed future economic benefit expected to be received from the assets.  Inputs used in the valuation included various market participant assumptions in order to project potential future cash flows, discounted at a rate commensurate with the risk involved.
			Useful Life			Estimated
			(in years)			Fair Value
	Intangible assets:
	Developed technology			7		$	9,394,000
	The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of acquisition (in thousands):
			Estimated
			Fair Value
	Current assets		$	236
	Property and equipment			260
	Intangible assets			9,394
	Total assets acquired			9,890
	Accrued and other current liabilities			(33	)
	Total fair value of the Joint Venture		$	9,857
	Acquisition-related transaction costs are not included as components of consideration transferred but have been accounted for as expenses in the period in which the costs are incurred.
	There was no revenue or earnings from the Joint Venture included in our consolidated results subsequent to the date of acquisition.  Had the acquisition occurred on January 1, 2013, consolidated revenue would not have been affected, but our consolidated net loss would have been reduced by $48,000, the amount of our year to date equity loss from investment in Joint Venture.
	The Company calculated the fair value of the purchase consideration on the acquisition date to be $4,928,000.  This was determined using a weighted probability assessment of the payment options available to Cytori.  Present value risk-adjusted discount rates applied to the purchase consideration ranged from 9.75% to 12.75%.  The fair value calculation of the purchase consideration resulted in a discount of $1,072,000, which will be amortized to interest expense over a weighted average expected term of 1.8 years.  On a quarterly basis, the Company will reassess the probabilities of the various payment options and expected term.  Changes in the expected term and the remaining discount amount as a result of the reassessment will be recognized prospectively as an adjustment to interest expense.  Upon final settlement of the purchase obligation, any difference between the amount paid and the carrying amount of the purchase obligation will be recorded as a gain or loss on extinguishment of the liability. As a result of this reassessment as of March 31, 2014 the Company believed it would settle the obligation for a total of $4.5 million (less any installment payments already made), which would have resulted in a gain of $0.6 million upon settlement.
	As of May 8, 2014, the Company’s obligation to Olympus had not been settled, and accordingly, the obligation increased by $1.5 million under an alternative payment option. This option calls for $6.0 million in total payments to be made by May 8, 2015. Since we have made payments totaling $2.6 million through June 30, our remaining payment obligation under this option is now $3.4 million.
	As a result of our quarterly reassessment, we have recorded additional interest expense of $145,000 during the quarter ended June 30, 2014 and have a remaining unrecognized future discount amount of approximately $700,000 as of June 30, 2014.
	Put/Calls and Guarantees
	Prior to the termination of the Joint Venture, the Shareholders’ Agreement between Cytori and Olympus provided that in certain specified circumstances of our insolvency or if we experienced a change in control, Olympus would have the rights to (i) repurchase our interests in the Joint Venture at the fair value of such interests or (ii) sell its own interests in the Joint Venture to Cytori (the “Put”) at the higher of (a) $22,000,000 or (b) the Put’s fair value.
	At December 31, 2012, the estimated fair value of the Put was $2,250,000.  The Put, as a previously existing contractual relationship between Olympus and Cytori, was cancelled as a result of the Joint Venture termination in May 2013 and therefore its related fair value decreased to zero as a result of the termination.  Fluctuations in the Put value were recorded in the consolidated condensed statements of operations as a component of change in fair value of option liabilities.

Partnership_Agreement_with_Lor

Partnership Agreement with Lorem Vascular	6 Months Ended
	Jun. 30, 2014
Partnership Agreement with Lorem Vascular [Abstract]	'
Partnership Agreement with Lorem Vascular	'
	5	Partnership Agreement with Lorem Vascular
	On October 29, 2013, we entered into a partnership with Lorem Vascular Pty. Ltd (“Lorem Vascular”), to commercialize Cytori Cell Therapy for the cardiovascular, renal and diabetes markets, in China, Hong Kong, Malaysia, Singapore and Australia (the “License/Supply Agreement”), and a Common Stock Purchase Agreement. On January 30, 2014 we entered into the Amended and Restated License/Supply Agreement with Lorem Vascular (the “Restated Agreement”) which restated the License/Supply Agreement in its entirety and expanded the licensed field to all uses excepting alopecia (hair loss). Under the Restated Agreement, Lorem Vascular committed to pay up to $500 million in license fees in the form of revenue milestones. In addition, Lorem is required to pay us 30% of their gross profits in China, Hong Kong and Malaysia for the term of the agreement. In addition, Lorem Vascular has agreed to purchase the Cytori Celution® System and consumables under the Restated Agreement.  Pursuant to the related Common Stock Purchase Agreement, Cytori sold Lorem Vascular 8 million shares of Cytori common stock at $3.00 per share for a total of $24 million. The Equity purchased was closed in two installments, the first half in November 2013, and the second half in January 2014.
	In addition, Lorem Vascular had initially committed to purchase approximately $7 million in Celution® devices and consumables, with an approximately $2 million order already completed, and an approximately $5 million order to be placed following regulatory approval in China.  Lorem and Cytori have implemented a regulatory plan for China and anticipate approval in 2014.

Longterm_Debt

Long-term Debt	6 Months Ended
	Jun. 30, 2014
Long-term Debt [Abstract]	'
Long-term Debt	'
	6	Long-term Debt
	On June 28, 2013 we entered into the Loan Agreement with the Lenders, pursuant to which the Lenders funded an aggregate principal amount of $27.0 million (Term Loans), subject to the terms and conditions set forth in the loan agreement.  The Term Loans accrue interest at a fixed rate of 9.75% per annum.  Pursuant to the Loan Agreement, we are required to make interest only payments through July 1, 2014 and thereafter we are required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loans through July 1, 2017, the maturity date. All unpaid principal and interest with respect to the Term Loans is due and payable in full on July 1, 2017. At maturity of the Term Loans, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment fee in an aggregate amount equal to $1,620,000.  In connection with the Term Loans, on June 28, 2013, we issued to the Lenders warrants to purchase up to an aggregate of 596,553 shares of our common stock at an exercise price of $2.26 per share.  These warrants are immediately exercisable and will expire on June 28, 2020.
	In connection with the Loan Agreement, we prepaid all outstanding amounts under the prior loan agreement, at which time the Company’s obligations under the prior loan agreement immediately terminated. The Company paid to the prior agent and the prior lenders approximately $18,866,000, consisting of the then outstanding principal balance due of approximately $17,325,000, accrued but unpaid interest of approximately $119,000, a final payment fee (net of fees waived or refunded by the Lenders under the new loan agreement) of approximately $1,078,000, a prepayment fee (net of fees waived or refunded by the Lenders under the new loan agreement) of approximately $312,000 and other customary lender fees and expenses.
	The net proceeds of the Term Loans, after payment of lender fees and expenses and prepaying all the outstanding amounts relating to the prior loan agreement, were approximately $7.8 million.
	For the continuing Lenders, we accounted for this amendment as a debt modification.  Accordingly, related fees of $1,942,000 were recorded as debt discount, and along with the unamortized debt discount will be amortized as an adjustment of interest expense using the effective interest method.  For one existing lender that did not participate in the Term Loans, the payoff of their loan was accounted for as debt extinguishment.  Accordingly, a loss on debt extinguishment of $708,000 was recorded, which includes that lender’s portion of unamortized fees and discounts along with prepayment and final payment fees.
	We allocated the aggregate proceeds of the Term Loans between the warrants and the debt obligations based on their relative fair values.  The fair value of the warrants issued to the Lenders was calculated utilizing the Black-Scholes option pricing model. We are amortizing the resulting additional discount of $949,000 to interest expense over the term of the loan using the effective interest method.  The overall effective interest rate for the Term Loans is 13.92%. The Term Loans are collateralized by the tangible assets of the company, including a security interest in substantially all of its existing and after-acquired assets.

Revenue_Recognition

Revenue Recognition

6 Months Ended

Jun. 30, 2014

Revenue Recognition [Abstract]

'

Revenue Recognition

'

7

Revenue Recognition

Product Sales

We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured. We recognize revenue for sales to new customers as cash is received as the risk of non-payment results in the conclusion that collection is not reasonably assured.

For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement.  If the other revenue recognition criteria are met, revenue for these product sales is recognized upon delivery to the customer, as all risks and rewards of ownership have been substantively transferred to the customer at that point.  For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities. Shipping and handling costs that are billed to our customers are classified as revenue.  The customer’s obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products. For sales where all revenue recognition criteria are not met, revenue is deferred and related inventory remains on our books.

For sales that include multiple deliverables, such as sales of our StemSource® Cell Bank (“cell bank”), we account for products or services (“deliverables”) separately rather than as a combined unit.  StemSource® Cell Banks typically consist of a complex array of equipment, proprietary knowledge, license rights, and services, including one or more StemSource® devices, a cryogenic freezer, measuring and monitoring equipment, and a database patient tracking system. In addition, we typically provide consulting, installation, and training services.  Web hosting, technical support and maintenance services are generally provided for a period of up to one year subsequent to the date of sale.  FASB authoritative guidance requires an evaluation of these deliverables to determine the appropriate “units of accounting” for purposes of revenue recognition.  Each cell bank is customized to provide the best solution for the customer.  Depending on customers’ needs, all or combination of the following units of accounting will apply to cell bank transactions:

●

initial consulting services;

●

license rights and standard operating procedures;

●

equipment and supplies;

●

installation services;

●

training services;

●

database hosting services;

●

technical support services; and

●

maintenance services.

FASB authoritative guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence (“VSOE”); (b) third-party evidence (“TPE”); or (c) management estimates.  This guidance requires arrangement consideration to be allocated at the inception of the arrangement to all deliverables using the relative selling price method.  For our cell bank sales, we establish relative selling prices for all deliverables based on vendor-specific quotes for comparable services when available.  In the absence of VSOE, we use competitors’ products or services considered largely interchangeable with our own or management’s best estimate.  Revenue allocated to each unit of accounting is calculated and recognized based on the relative selling price of each deliverable.  Future services such as web hosting and ongoing maintenance are deferred and recognized into income as the services are provided, generally over one year following the installation of the equipment.

Concentration of Significant Customers

Five distributors comprised 71% of our revenue recognized for the six months ended June 30, 2014.  Three distributors accounted for 78% of total outstanding accounts receivable as of June 30, 2014.

Two distributors comprised 38% of our revenue recognized for the six months ended June 30, 2013.  Two direct customers and two distributors accounted for 58% of total outstanding accounts receivable as of June 30, 2013.

Product revenues, classified by geographic location, are as follows:

Six months ended

30-Jun-14

30-Jun-13

Product

% of

Product

% of

Revenues

Total

Revenues

Total

North America

$

264,000

14

%

$

583,000

21

%

Japan

1,263,000

64

%

1,487,000

53

%

Europe

438,000

22

%

625,000

22

%

Other countries

—

—

105,000

4

%

Total product revenues

$

1,965,000

100

%

$

2,800,000

100

%

Research and Development

We earn revenue for performing tasks under research and development agreements with both commercial enterprises, such as Olympus and Senko, and governmental agencies like the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA).  Revenue earned under development agreements with commercial enterprises is classified as development revenues.  Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues.  Government contract revenue is recorded at the gross amount of the reimbursement.  The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations.

In the third quarter of 2012, we were awarded a contract to develop a new countermeasure for thermal burns valued at up to $106 million with BARDA. The initial base period included $4.7 million over two years and covered preclinical research and continued development of Cytori’s Celution® system to improve cell processing. The additional contract options, if fully executed, cover clinical development through FDA approval under a device-based PMA regulatory pathway. This is a cost reimbursement contract and related government contract revenue was recorded at the gross amount of reimbursement starting in the fourth quarter of 2012.  In July 2014, we received from BARDA preliminary notice of intent to exercise ‘Option 1’ under the master contract. The notice of intent followed an In-Process Review meeting with BARDA in June, in which they confirmed that Cytori had completed the objectives of the base contract to the government’s satisfaction. We are currently in negotiations with BARDA to finalize additions to the Statement of Work which would extend the contract through September 2016.

We received funds from Olympus and Olympus-Cytori, Inc. during 2005 and 2006.   We recorded upfront fees totaling $28,311,000 as deferred revenues, related party.  In exchange for these proceeds, we agreed to (a) provide Olympus-Cytori, Inc. an exclusive and perpetual license to our Celution® System device technology and certain related intellectual property, and (b) provide future development contributions related to commercializing the Celution® System platform.  The license and development services were not separable and as a result the recognition of this deferred amount as revenue required achievement of service related milestones, under a proportional performance methodology.  Revenue was recognized as the above mentioned R&D milestones were completed. Of the amounts received and deferred, we recognized the last remaining development revenue of $638,000 during the three months ended March 31, 2013 as a result of the United States Court of Appeals upholding the FDA’s previous determination that our cell processing devices were not substantially equivalent to the cited predicate devices.  The recognition of revenue associated with this event reflects the completion of our efforts expended to use commercially reasonable efforts to obtain device regulatory approvals in the United States as it pertains to the 510(k) pathway. As of June 30, 2014, there are no deferred amounts under this contract.

Refer to Note 14 for discussion about arrangement with Senko.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventories [Abstract]	'
Inventories	'
	8	Inventories
	Inventories are carried at the lower of cost or market, determined on the first-in, first-out (FIFO) method.
	Inventories consisted of the following:
			June 30,		December 31,
			2014		2013
	Raw materials		$	1,466,000	$	1,315,000
	Work in process			772,000		232,000
	Finished goods			2,250,000		2,147,000
			$	4,488,000	$	3,694,000

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2014
Share-Based Compensation [Abstract]	'
Share-Based Compensation	'
	9	Share-Based Compensation
	Stock Options
	During the second quarter of 2014 we issued to our executive officers and certain non-executive employees options to purchase an aggregate of 1,565,000 shares of our common stock with four-year vesting. The grant date fair value of the awards granted to our officers and employees was $1.61 per share for options with an exercise price of $2.38 (which was the fair market value of our common stock on the date of grant). The resulting share-based compensation expense of $2,525,000, net of estimated forfeitures will be recognized over the respective vesting periods.
	During the first quarter of 2014, we issued to our directors options to purchase an aggregate of 96,180 shares of our common stock, with two-year vesting. The grant date fair value of the awards granted to our officers was $1.75 per share for options with an exercise price of $2.57 (which was the fair market value of our common stock on the date of grant). The resulting share-based compensation expense of $168,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.
	During the first quarter of 2013, we issued to our directors and executive officers options to purchase an aggregate of 1,897,000 shares of our common stock, with four-year vesting for our officers and two-year vesting for our directors. The grant date fair value of the awards granted to our officers was $1.80 per share for options with an exercise price of $2.74 (which was the fair market value of our common stock on the date of grant) and $1.49 per share for options with an exercise price of $5.00, respectively.  The grant date fair value of the awards granted to our directors was $1.84 per share for options with an exercise price of $2.80 (which was the fair market value of our common stock on the date of grant). The resulting share-based compensation expense of $3,235,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.
	During the first quarter of 2013, we issued a grant to our non-executive employees options to purchase an aggregate of 552,350 shares of our common stock, with four-year vesting. The grant date fair values of the awards were $1.92 per share and $1.64 per share, respectively, due to the awards being granted on two different dates. The resulting share-based compensation expense of $974,000, net of estimated forfeitures, will be recognized as expense over the respective vesting periods.
	Restricted Stock Awards
	During the second quarter of 2014, we issued to our directors 31,508 shares of restricted stock. The stock award vests on January 2, 2015 and the resulting share-based compensation expense of $76,000 will be recognized as expense over the vesting period.
	During the first quarter of 2014, we issued to our directors 63,300 shares of restricted stock. The stock award vests on January 2, 2015 and the resulting share-based compensation expense of $162,700 will be recognized as expense over the vesting period.
	Performance-Based Restricted Stock Awards
	In January 2012, we granted 276,375 performance-based restricted stock awards under the 2004 Equity Incentive Plan.  The awards provided certain employees until December 31, 2012 to achieve certain performance goals established by the Compensation Committee. In January 2013, the Compensation Committee modified the awards to allow a portion of the awards to continue vesting based on partial achievement of the performance goals.  As a result of this modification, 86,229 shares with fair value of $2.74 per share will continue vesting under the modified terms of the grant that would have been cancelled under the original terms.  Since we had not recognized any expense relating to these shares through December 31, 2012, additional compensation expense $236,000 resulting from this modification was recognized from the modification date through the vesting date of January 2014.  We recognized $9,800 of compensation expense related to performance-based awards during the six months ended June 30, 2014.

Loss_per_Share

Loss per Share	6 Months Ended
	Jun. 30, 2014
Loss per Share [Abstract]	'
Loss per Share	'
	10	Loss per Share
	Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented.
	We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the three and six months ended June 30, 2014 and 2013, as their inclusion would be antidilutive.  Potentially dilutive common shares excluded from the calculations of diluted loss per share were 22,507,907 for the three and six month periods ended June 30, 2014 and 19,536,812 for the three and six month periods ended June 30, 2013, respectively.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Loss [Abstract]	'
Accumulated Other Comprehensive Loss	'
	11	Accumulated Other Comprehensive Loss
	During the first quarter of 2013, we determined that the functional currency of our Japanese subsidiary changed from the US Dollar to the Japanese Yen due to significant changes in economic facts and circumstances of our Japan subsidiary.  As a result of this change, a portion of the foreign exchange gain or loss will be classified as foreign currency translation adjustments within other comprehensive income or loss. Our comprehensive loss includes net loss and foreign currency translation adjustments. See the unaudited consolidated condensed statements of operations and comprehensive loss for the effect of foreign currency translation adjustments.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	12	Commitments and Contingencies
	We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements was estimated based on current schedules of pre-clinical and clinical studies in progress.  As of June 30, 2014, we have pre-clinical research study obligations of $23,000 (all of which are expected to be complete within a year) and clinical research study obligations of $7,605,000 ($5,755,000 of which are expected to be complete within a year).  Should the timing of the pre-clinical and clinical trials change, the timing of the payment of these obligations would also change.
	During 2008, we entered into a supply agreement with a minimum purchase requirements clause.  As of June 30, 2014, we have minimum purchase obligations of $850,000 (all of which are expected to be paid within a year).
	We have entered into several lease agreements for our headquarters office location as well as international office locations. As of June 30, 2014, we have remaining lease obligations of $6,333,000 ($1,905,000 of which are expected to be completed within a year).
	We are subject to various claims and contingencies related to legal proceedings.  Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions.  Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate.  Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole.
	Refer to note 6 for a discussion of our commitments and contingencies related to our long-term obligations.
	Refer to note 4 for a discussion of our commitments and contingencies related to our transactions with Olympus.
	Refer to note 14 for a discussion of our commitments and contingencies related to our arrangements with Senko.

Sale_and_Exclusive_LicenseSupp

Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC	6 Months Ended
	Jun. 30, 2014
Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC [Abstract]	'
Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC	'
	13	Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC
	On July 30, 2013, we entered into a Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC (“Bimini”), pursuant to which we sold to Bimini substantially all of the assets (other than certain retained rights and licenses) of our Puregraft® product line, a series of standalone fat transplantation products that were developed to improve the predictability of outcomes for autologous fat grafting and aesthetic body contouring. The aggregate value of the consideration paid by Bimini at the execution of the agreement was $5.0 million.
	In connection with the sale, Bimini granted to the Company an exclusive, perpetual, royalty bearing license to market and sell the Puregraft products for use in combination with adipose derived regenerative cells, and non-exclusive rights for use in connection with the Company’s licensed cell and tissue banks (in addition to certain Company retained ownership rights in the technology). The Company will supply Puregraft products to Bimini on an interim basis until the Company transfers the manufacturing of the Puregraft products to Bimini. After the transfer, Bimini will supply the Puregraft products to the Company.
	Pursuant to the sale agreement, the Company has also granted to Bimini the global, exclusive, perpetual, irrevocable royalty bearing license to purchase from Cytori, use and sell the Celution® System products for Alopecia (hair loss). Cytori will supply Celution devices and consumable sets to Bimini, and Bimini will be responsible for all costs associated with commercial development in the Alopecia market.
	The agreement includes certain obligations to be performed by the Company on the behalf of Bimini, which includes transferring the manufacturing of Puregraft products to an agreed upon third party on or before December 31, 2014 and training. The Company recorded a gain on the Puregraft divestiture of $4.5 million in 2013, and has a remaining obligation of approximately $215,000 in future transfer and training obligations, as of June 30, 2014. Bimini is obligated to make certain additional milestone payments to the Company (in an aggregate amount of up to $10.0 million), contingent upon the achievement of certain milestones relating to Bimini’s gross profits from sales of the Puregraft products.

Thin_Film_Japan_Distribution_A

Thin Film Japan Distribution Agreement	6 Months Ended
	Jun. 30, 2014
Thin Film Japan Distribution Agreement [Abstract]	'
Thin Film Japan Distribution Agreement	'
	14	Thin Film Japan Distribution Agreement
	In 2004, the Company entered into a Distribution Agreement with Senko.  Under this agreement, we granted to Senko an exclusive license to sell and distribute certain Thin Film products in Japan and are responsible for the completion of the initial regulatory application to the Ministry of Health, Labor and Welfare (“MHLW”) and commercialization of the Thin Film product line in Japan.  The Distribution Agreement with Senko commences upon “commercialization.”  Essentially, commercialization occurs when one or more Thin Film product registrations are completed with the MHLW.  At the inception of this arrangement, we received a $1,500,000 license fee which was recorded as deferred revenues in 2004.  Half of the license fee was refundable if the parties agree commercialization is not achievable and a proportional amount was refundable if we terminate the arrangement, other than for material breach by Senko, before three years post-commercialization.  We have also received $1,250,000 in milestone payments from Senko.
	In February 2013, we entered into a mutual termination and release agreement with Senko, whereby the Distribution Agreement and all Senko rights, licenses and privileges granted under the Distribution Agreement terminated and reverted to the Company.  As a result of this Termination Agreement, we are obligated to pay Senko $1,200,000 in six quarterly installment payments of $200,000 each through May 2014 (all of which has been paid).  At the time of the Termination Agreement, we had a balance of $2,379,000 in deferred revenues on our balance sheet relating to the payments received from Senko in the past pursuant to the Distribution Agreement.  At the time of the Termination Agreement we accrued $1,200,000 of the termination fee, and recognized the remaining $1,179,000 in development revenues which reflects the Company’s efforts towards commercialization under the agreement. As of June 30, 2014, we have no remaining termination fee obligation.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	15	Fair Value Measurements
	Fair value measurements are market-based measurements, not entity-specific measurements.  Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability.  We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values.  The basis for fair value measurements for each level within the hierarchy is described below:
	·  Level 1: Quoted prices in active markets for identical assets or liabilities.
	·  Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.
	·  Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.
	The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis
			Balance as of		Basis of Fair Value Measurements
			30-Jun-14		Level 1		Level 2		Level 3
	Assets:
	Cash equivalents		$	4,644,000	$	4,644,000	$	—	$	—
			Balance as of		Basis of Fair Value Measurements
			31-Dec-13		Level 1		Level 2		Level 3
	Assets:
	Cash equivalents		$	4,644,000	$	4,644,000	$	—	$	—
	We use quoted market prices to determine the fair value of our cash equivalents, which consist of money market funds that are classified in Level 1 of the fair value hierarchy.

Fair_Value

Fair Value	6 Months Ended
	Jun. 30, 2014
Fair Value [Abstract]	'
Fair Value	'
	16	Fair Value
	Financial Instruments
	We disclose fair value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at June 30, 2014 and December 31, 2013, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts.
	The carrying amounts for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments.
	We utilize quoted market prices to estimate the fair value of our fixed rate debt, when available.  If quoted market prices are not available, we calculate the fair value of our fixed rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to the debt.
	At June 30, 2014 and December 31, 2013, the aggregate fair value and the carrying value of the Company’s fixed rate long-term debt were as follows:
			30-Jun-14				31-Dec-13
			Fair Value		Carrying Value		Fair Value		Carrying Value
	Fixed rate long-term debt		$	26,712,000	$	26,803,000	$	26,207,000	$	26,241,000
	Carrying value is net of debt discount of $1,817,000 and $2,379,000 as of June 30, 2014 and December 31, 2013, respectively.
	The fair value of debt is classified as Level 3 in the fair value hierarchy as some of the inputs to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means. These inputs include the monthly payments and term of the loan, the stated interest rate, the estimated market interest rate for similar debt, and the amount and timing of the final payment fee.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	17	Stockholders’ Equity
	Common Stock
	In December 2012, we entered into an underwriting agreement with Lazard Capital Markets, LLC (underwriter), relating to the issuance and sale of 7,020,000 shares of our common stock.  The price to the public in this offering was $2.85 per share and the underwriter purchased the shares from us at a price of $2.69 per share.  The transaction was completed on December 19, 2012 raising approximately $20,007,000 in gross proceeds before deducting underwriting discounts and commissions and other offering expenses payable by us. Under the terms of the underwriting agreement, we granted the underwriter an option, exercisable for 30 days, to purchase up to an additional 1,053,000 shares.
	In January 2013, the underwriter exercised this option and as a result we sold an additional 1,053,000 shares raising approximately $3,001,000 in gross proceeds before deducting underwriting discounts and commissions and other offering expenses payable by us.
	In October 2013, we entered into a Common Stock Purchase Agreement with Lorem Vascular for the purchase of 8,000,000 shares at $3.00 per share. The transaction occurred in two separate closings of 4,000,000 shares each. The first closing occurred in November 2013, and the second closing occurred in January 2014. As of December 31, 2013, we received $15,000,000 of the gross proceeds, $12,000,000 for the first closing and $3,000,000 towards the second closing. The balance of $9,000,000 in gross proceeds required to complete the second closing were received in January 2014.
	In May 2014, we and 47 holders of warrants to purchase a total of 3,156,238 shares of the Company’s common stock, $0.001 par value per share, issued in a private offering in May 2009, agreed to extend the expiration date of the warrants from May 14, 2014 to May 14, 2015 and increase the exercise price of the warrants from $2.62 per share to $3.50 per share pursuant to an Amendment to Warrant to Purchase Common Stock. One holder of warrants did not agree to the Amendment, and their warrants, covering 38,500 shares of Common Stock, expired unexercised on May 14, 2014 in accordance with the original terms.
	In May 2014, we entered into subscription agreements with certain institutional investors pursuant to which sold a total of 4,048,584 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a purchase price of $2.47 per unit, in a registered direct offering. Each warrant will have an exercise price of $3.00 per share, will be exercisable immediately after issuance and will expire five years from the date of issuance. The transaction was completed on June 4, 2014 raising approximately $10,000,000 in gross proceeds before deducting any offering expenses or fees payable by us. Under the terms of our Placement Agent Agreement, we granted WBB Securities, LLC warrants to purchase 202,429 shares of common stock. The placement agent warrants will have the same terms as the warrants issued to the purchasers in the offering, except that such warrants will have an exercise price of $3.09.
	Other Related Party Transactions
	During the six months ended June 30, 2013, we incurred approximately $45,000, in royalty costs in connection with our sales of our Celution® 800/CRS System products to the European and Asia-Pacific reconstructive surgery market, pursuant to our License and Royalty Agreement and the Amended License/Commercial Agreement with the Olympus-Cytori, Inc. joint venture. There were no comparable royalty costs during the six months ended June 30, 2014.
	Additionally, refer to note 4 for a discussion of related party transactions with Olympus.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2014
Basis of Presentation [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	Our accompanying unaudited consolidated condensed financial statements as of June 30, 2014 and for the three and six months ended June 30, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.  Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.  Our consolidated condensed balance sheet at June 30, 2014 has been derived from the audited financial statements at December 31, 2013, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (the Company) have been included.  Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.  These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our annual report on Form 10-K for the year ended December 31, 2013.

Use_of_Estimates_Policies

Use of Estimates (Policies)	6 Months Ended
	Jun. 30, 2014
Use of Estimates [Abstract]	'
Use of Estimates	'
		Use of Estimates
	The preparation of Consolidated Condensed Financial Statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period.  Our most significant estimates and critical accounting policies involve recognizing revenue, determining the assumptions used in measuring share-based compensation expense and valuing allowances for doubtful accounts and inventories.
	Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the Consolidated Condensed Financial Statements in the periods they are determined to be necessary.

Revenue_Recognition_Policies

Revenue Recognition (Policies)

6 Months Ended

Jun. 30, 2014

Revenue Recognition [Abstract]

'

Revenue Recognition

'

Revenue Recognition

Product Sales

We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured. We recognize revenue for sales to new customers as cash is received as the risk of non-payment results in the conclusion that collection is not reasonably assured.

For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement.  If the other revenue recognition criteria are met, revenue for these product sales is recognized upon delivery to the customer, as all risks and rewards of ownership have been substantively transferred to the customer at that point.  For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities. Shipping and handling costs that are billed to our customers are classified as revenue.  The customer’s obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products. For sales where all revenue recognition criteria are not met, revenue is deferred and related inventory remains on our books.

For sales that include multiple deliverables, such as sales of our StemSource® Cell Bank (“cell bank”), we account for products or services (“deliverables”) separately rather than as a combined unit.  StemSource® Cell Banks typically consist of a complex array of equipment, proprietary knowledge, license rights, and services, including one or more StemSource® devices, a cryogenic freezer, measuring and monitoring equipment, and a database patient tracking system. In addition, we typically provide consulting, installation, and training services.  Web hosting, technical support and maintenance services are generally provided for a period of up to one year subsequent to the date of sale.  FASB authoritative guidance requires an evaluation of these deliverables to determine the appropriate “units of accounting” for purposes of revenue recognition.  Each cell bank is customized to provide the best solution for the customer.  Depending on customers’ needs, all or combination of the following units of accounting will apply to cell bank transactions:

●

initial consulting services;

●

license rights and standard operating procedures;

●

equipment and supplies;

●

installation services;

●

training services;

●

database hosting services;

●

technical support services; and

●

maintenance services.

FASB authoritative guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence (“VSOE”); (b) third-party evidence (“TPE”); or (c) management estimates.  This guidance requires arrangement consideration to be allocated at the inception of the arrangement to all deliverables using the relative selling price method.  For our cell bank sales, we establish relative selling prices for all deliverables based on vendor-specific quotes for comparable services when available.  In the absence of VSOE, we use competitors’ products or services considered largely interchangeable with our own or management’s best estimate.  Revenue allocated to each unit of accounting is calculated and recognized based on the relative selling price of each deliverable.  Future services such as web hosting and ongoing maintenance are deferred and recognized into income as the services are provided, generally over one year following the installation of the equipment.

Concentration of Significant Customers

Five distributors comprised 71% of our revenue recognized for the six months ended June 30, 2014.  Three distributors accounted for 78% of total outstanding accounts receivable as of June 30, 2014.

Two distributors comprised 38% of our revenue recognized for the six months ended June 30, 2013.  Two direct customers and two distributors accounted for 58% of total outstanding accounts receivable as of June 30, 2013.

Product revenues, classified by geographic location, are as follows:

Six months ended

30-Jun-14

30-Jun-13

Product

% of

Product

% of

Revenues

Total

Revenues

Total

North America

$

264,000

14

%

$

583,000

21

%

Japan

1,263,000

64

%

1,487,000

53

%

Europe

438,000

22

%

625,000

22

%

Other countries

—

—

105,000

4

%

Total product revenues

$

1,965,000

100

%

$

2,800,000

100

%

Research and Development

We earn revenue for performing tasks under research and development agreements with both commercial enterprises, such as Olympus and Senko, and governmental agencies like the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA).  Revenue earned under development agreements with commercial enterprises is classified as development revenues.  Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues.  Government contract revenue is recorded at the gross amount of the reimbursement.  The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations.

In the third quarter of 2012, we were awarded a contract to develop a new countermeasure for thermal burns valued at up to $106 million with BARDA. The initial base period included $4.7 million over two years and covered preclinical research and continued development of Cytori’s Celution® system to improve cell processing. The additional contract options, if fully executed, cover clinical development through FDA approval under a device-based PMA regulatory pathway. This is a cost reimbursement contract and related government contract revenue was recorded at the gross amount of reimbursement starting in the fourth quarter of 2012.  In July 2014, we received from BARDA preliminary notice of intent to exercise ‘Option 1’ under the master contract. The notice of intent followed an In-Process Review meeting with BARDA in June, in which they confirmed that Cytori had completed the objectives of the base contract to the government’s satisfaction. We are currently in negotiations with BARDA to finalize additions to the Statement of Work which would extend the contract through September 2016.

We received funds from Olympus and Olympus-Cytori, Inc. during 2005 and 2006.   We recorded upfront fees totaling $28,311,000 as deferred revenues, related party.  In exchange for these proceeds, we agreed to (a) provide Olympus-Cytori, Inc. an exclusive and perpetual license to our Celution® System device technology and certain related intellectual property, and (b) provide future development contributions related to commercializing the Celution® System platform.  The license and development services were not separable and as a result the recognition of this deferred amount as revenue required achievement of service related milestones, under a proportional performance methodology.  Revenue was recognized as the above mentioned R&D milestones were completed. Of the amounts received and deferred, we recognized the last remaining development revenue of $638,000 during the three months ended March 31, 2013 as a result of the United States Court of Appeals upholding the FDA’s previous determination that our cell processing devices were not substantially equivalent to the cited predicate devices.  The recognition of revenue associated with this event reflects the completion of our efforts expended to use commercially reasonable efforts to obtain device regulatory approvals in the United States as it pertains to the 510(k) pathway. As of June 30, 2014, there are no deferred amounts under this contract.

Refer to Note 14 for discussion about arrangement with Senko.

Transactions_with_Olympus_Corp1

Transactions with Olympus Corporation (Tables)	6 Months Ended
	Jun. 30, 2014
Transactions with Olympus Corporation [Abstract]	'
Schedule of Acquired Intangible Assets	'
	Inputs used in the valuation included various market participant assumptions in order to project potential future cash flows, discounted at a rate commensurate with the risk involved.
		Useful Life			Estimated
		(in years)			Fair Value
	Intangible assets:
	Developed technology		7		$	9,394,000
Schedule of Assets Acquired and Liabilities Assumed	'
	The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of acquisition (in thousands):
		Estimated
		Fair Value
	Current assets	$	236
	Property and equipment		260
	Intangible assets		9,394
	Total assets acquired		9,890
	Accrued and other current liabilities		(33	)
	Total fair value of the Joint Venture	$	9,857

Revenue_Recognition_Tables

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2014
Revenue Recognition [Abstract]	'
Product Revenues by Geographic Location	'
	Product revenues, classified by geographic location, are as follows:
		Six months ended
		30-Jun-14					30-Jun-13
		Product		% of			Product		% of
		Revenues		Total			Revenues		Total
	North America	$	264,000		14	%	$	583,000		21	%
	Japan		1,263,000		64	%		1,487,000		53	%
	Europe		438,000		22	%		625,000		22	%
	Other countries		—		—			105,000		4	%
	Total product revenues	$	1,965,000		100	%	$	2,800,000		100	%

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventories [Abstract]	'
Inventory	'
	Inventories consisted of the following:
		June 30,		December 31,
		2014		2013
	Raw materials	$	1,466,000	$	1,315,000
	Work in process		772,000		232,000
	Finished goods		2,250,000		2,147,000
		$	4,488,000	$	3,694,000

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]	'
Assets and Liabilities Measured at Fair Value	'
	The following table provides a summary of the recognized assets and liabilities that we measure at fair value on a recurring basis
		Balance as of		Basis of Fair Value Measurements
		30-Jun-14		Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	4,644,000	$	4,644,000	$	—	$	—
		Balance as of		Basis of Fair Value Measurements
		31-Dec-13		Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	4,644,000	$	4,644,000	$	—	$	—

Fair_Value_Tables

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value [Abstract]	'
Fair Value and Carrying Value of Long-term Debt	'
	At June 30, 2014 and December 31, 2013, the aggregate fair value and the carrying value of the Company’s fixed rate long-term debt were as follows:
		30-Jun-14				31-Dec-13
		Fair Value		Carrying Value		Fair Value		Carrying Value
	Fixed rate long-term debt	$	26,712,000	$	26,803,000	$	26,207,000	$	26,241,000

Capital_Availability_Details

Capital Availability (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Capital Availability [Abstract]	'	'	'	'	'	'
Net loss	$11,828,000	$3,211,000	$22,228,000	$10,877,000	'	'
Accumulated deficit	323,133,000	'	323,133,000	'	300,905,000	'
Net cash used	'	'	18,137,000	17,014,000	'	'
Cash and cash equivalents	12,760,000	13,621,000	12,760,000	13,621,000	15,506,000	25,717,000
Periodic payments beginning August 2014	'	'	868,000	'	'	'
Loan amount in event of default due and payable	$28,670,000	'	$28,670,000	'	'	'

Transactions_with_Olympus_Corp2

Transactions with Olympus Corporation (Details) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

31-May-13

Dec. 31, 2012

8-May-14

27-May-13

Mar. 31, 2014

8-May-14

8-May-13

27-May-13

27-May-13

Jun. 30, 2014

Acquired Olympus Ownership [Member]

Acquired Olympus Ownership [Member]

Acquired Olympus Ownership [Member]

Acquired Olympus Ownership [Member]

Acquired Olympus Ownership [Member]

Acquired Olympus Ownership [Member]

Acquired Olympus Ownership [Member]

Acquired Olympus Ownership [Member]

Minimum [Member]

Maximum [Member]

Developed Technology [Member]

Acquisition of Olympus' Interest in the Joint Venture [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity interest acquired (in hundredths)

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

Acquisition agreement date

'

'

'

'

'

'

'

27-May-13

'

'

'

'

'

'

Remeasurement gain

$0

$4,892,000

$0

$4,892,000

'

'

'

'

'

'

'

'

'

'

Payment obligation under termination agreement

'

'

'

'

'

'

'

'

'

2,600,000

'

4,500,000

16,000,000

'

Payment installment period

'

'

'

'

'

'

'

'

'

'

'

'1 year

'6 years

'

Installment payment amount description

'

'

'

'

'

'

'

'Installment payments will be calculated quarterly based on 5% of Cytoribs gross sales receipts for all products sold. If Cytori receives an aggregate $35,000,000 in cash through strategic or financing arrangements during the first year of the Termination Agreement, Cytori will pay $4,500,000 upon request of Olympus as full and complete consideration under the Agreement.

'

'

'

'

'

'

Gross sales receipts (in hundredths)

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

Limit for cash through strategic or financing arrangements

'

'

'

'

'

'

'

35,000,000

'

'

'

'

'

'

Required payment for acquisition

'

'

'

'

'

'

'

4,500,000

'

'

'

'

'

'

Inputs used in valuation of acquired intangible assets [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful life (in years)

'

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

Estimated fair value

'

'

'

'

'

'

'

'

'

'

9,394,000

'

'

9,394,000

Fair value of purchase consideration

'

'

'

'

'

'

'

4,928,000

'

'

'

'

'

'

Present value risk-adjusted discount rates (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

9.75%

12.75%

'

Unamortized discount resulting from fair value calculation of purchase obligations

'

'

'

'

'

'

'

1,072,000

'

'

'

'

'

'

Weighted average expected term for amortization of purchase obligation

'

'

'

'

'

'

'

'1 year 9 months 18 days

'

'

'

'

'

'

Year-to-date equity loss from investment in Joint Venture

'

'

'

'

'

'

'

48,000

'

'

'

'

'

'

Additional Interest Expense

145,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining Unrecognized Future Discount

700,000

'

700,000

'

'

'

'

'

'

'

'

'

'

'

Gain on remeasurement of purchase obligation

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

Increase in settlement obligation

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

Fair value of the assets acquired and liabilities assumed at the date of acquisition [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Current assets

'

'

'

'

'

'

'

'

'

'

236,000

'

'

'

Property and equipment

'

'

'

'

'

'

'

'

'

'

260,000

'

'

'

Intangible assets

'

'

'

'

'

'

'

'

'

'

9,394,000

'

'

9,394,000

Total assets acquired

'

'

'

'

'

'

'

'

'

'

9,890,000

'

'

'

Accrued and other current liabilities

'

'

'

'

'

'

'

'

'

'

-33,000

'

'

'

Total fair value of the Joint Venture

'

'

'

'

'

'

'

'

'

'

9,857,000

'

'

'

Put/Calls and Guarantees [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Put option, repurchase floor

22,000,000

'

22,000,000

'

'

'

'

'

'

'

'

'

'

'

Option liability

'

'

'

'

$0

$2,250,000

'

'

'

$6,000,000

'

'

'

'

Partnership_Agreement_with_Lor1

Partnership Agreement with Lorem Vascular (Details) (USD $)	6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 30, 2014
Product Purchase Commitment [Member]	'
Partnership Agreement [Line Items]	'
Second purchase commitment	$5
Lorem Vascular [Member] | Equity Purchases [Member]	'
Partnership Agreement [Line Items]	'
Shares of unregistered stock purchased (in shares)	8
Equity purchase price (in dollars per share)	$3
Proceeds from sale of shares	24
Number of installments in equity purchases	2
Lorem Vascular [Member] | Product Purchase Commitment [Member]	'
Partnership Agreement [Line Items]	'
Total commitment	500
Gross profits percentage (in hundredths)	30.00%
First purchase commitment	7
Order already placed	$2

Longterm_Debt_Details

Long-term Debt (Details) (USD $)	3 Months Ended		6 Months Ended		0 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 28, 2013	Jun. 28, 2013
					Term Loan [Member]	Term Loan [Member]
						Final Payment [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'
Origination date	'	'	'	'	28-Jun-13	'
Original loan amount	'	'	'	'	$27,000,000	'
Interest rate (in hundredths)	'	'	'	'	9.75%	'
Maturity date	'	'	'	'	1-Jul-17	'
Fees amount associated with loan	'	'	'	'	1,620,000	1,942,000
Date from which warrants are exercisable	'	'	'	'	28-Jun-13	'
Warrant expiration date	'	'	'	'	28-Jun-20	'
Repayment of long term debt	'	'	0	22,292,000	18,866,000	'
Term Loan remaining balance at date of Amendment	'	'	'	'	17,325,000	'
Accrued but unpaid interest	'	'	'	'	119,000	'
Final payment fee	'	'	'	'	1,078,000	'
Prepayment fee	'	'	'	'	312,000	'
Net proceeds of the Term Loan, after payment of lender fees and expenses	'	'	0	27,000,000	7,800,000	'
Unamortized debt discount	'	'	'	'	949,000	'
Effective interest rate (in hundredths)	'	'	'	'	13.92%	'
Loss on debt extinguishment	$0	$708,000	$0	$708,000	$708,000	'

Revenue_Recognition_Details

Revenue Recognition (Details) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Mar. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Olympus and Olympus-Cytori [Member]

BARDA Contract [Member]

BARDA Contract [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

North America [Member]

North America [Member]

Japan [Member]

Japan [Member]

Europe [Member]

Europe [Member]

Other countries [Member]

Other countries [Member]

Revenue Recognized [Member]

Revenue Recognized [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Distributor

Distributor

Customer

Distributor

Customer

Distributor

Customer

Revenue Recognition [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of services provided subsequent to date of sale

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues from External Customers and Long-Lived Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of distributors

'

'

'

'

'

'

'

'

'

'

5

2

3

2

'

'

'

'

'

'

'

'

Number of customers

'

'

'

'

'

'

'

'

'

'

'

2

2

2

'

'

'

'

'

'

'

'

Product revenues

$935,000

$1,408,000

'

$1,965,000

$2,800,000

'

'

'

'

'

'

'

'

'

$264,000

$583,000

$1,263,000

$1,487,000

$438,000

$625,000

$0

$105,000

Concentration risk percentage (in hundredths)

'

'

'

100.00%

100.00%

'

'

'

'

'

71.00%

38.00%

78.00%

58.00%

14.00%

21.00%

64.00%

53.00%

22.00%

22.00%

0.00%

4.00%

Research and Development Arrangements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenues, related party

'

'

'

'

'

'

'

28,311,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue, related party, revenue recognized

'

'

638,000

'

'

0

2,882,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Costs associated with the development device

4,674,000

4,150,000

'

8,966,000

7,869,000

'

'

'

106,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development arrangement with federal government, customer funding to offset costs incurred

'

'

'

'

'

'

'

'

$4,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development arrangement, initial base period

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventories [Abstract]	'	'
Raw materials	$1,466,000	$1,315,000
Work in process	772,000	232,000
Finished goods	2,250,000	2,147,000
Inventory, net	$4,488,000	$3,694,000

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

Mar. 31, 2013

Mar. 31, 2013

Jun. 30, 2014

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2012

Non-Executive Employee [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock Awards [Member]

Restricted Stock Awards [Member]

Performance-Based Restricted Stock Awards [Member]

Performance-Based Restricted Stock Awards [Member]

Performance-Based Restricted Stock Awards [Member]

Executive officers [Member]

Directors [Member]

Directors [Member]

Directors and Executive Officers [Member]

Non-Executive Employee [Member]

Executive Officers and Non-Executive Employees [Member]

Directors [Member]

Directors [Member]

Stock Options [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Options granted (in shares)

'

'

96,180

'

1,897,000

552,350

1,565,000

'

'

'

'

'

Vesting period

'

'4 years

'2 years

'2 years

'

'4 years

'4 years

'

'

'

'

'

Options, grant date fair value (in dollars per share)

$1.64

$1.80

$1.75

$1.84

'

$1.92

$1.61

'

'

'

'

'

Exercisable fair value (in dollars per share)

'

$2.74

'

$2.80

$1.49

'

'

'

'

'

'

'

Exercised (in dollars per share)

'

'

$2.57

'

$5

'

$2.38

'

'

'

'

'

Allocated share-based compensation expense

'

'

$168,000

'

$3,235,000

$974,000

$2,525,000

$76,000

$162,700

'

'

'

Restricted Stock Award [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock issued during period (in shares)

'

'

'

'

'

'

'

31,508

63,300

'

'

'

Performance Based Restricted Stock Awards [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Recognized compensation expense related to awards

'

'

'

'

'

'

'

'

'

'

9,800

'

Number of shares that continue to vest under grant (in shares)

'

'

'

'

'

'

'

'

'

'

'

86,229

Fair value of shares that continue to vest under grant (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

$2.74

Additional compensation expense not yet recognized

'

'

'

'

'

'

'

'

'

'

'

$236,000

Restricted Stock Awards, Performance-Based Restricted Stock Awards [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

'

'

'

'

'

'

'

'

'

'

'

276,375

Vested (in shares)

'

'

'

'

'

'

'

'

'

0

'

'

Loss_per_Share_Details

Loss per Share (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Loss per Share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	22,507,907	19,536,812	22,507,907	19,536,812

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	Jun. 30, 2014
Clinical Research Study Obligations [Member]	'
Recorded Unconditional Purchase Obligation [Line Items]	'
Purchase obligation, due in next twelve months	$5,755,000
Purchase obligation	7,605,000
Pre Clinical Research Study Obligations [Member]	'
Recorded Unconditional Purchase Obligation [Line Items]	'
Purchase obligation, due in next twelve months	23,000
Minimum Purchase Obligation, Supply Agreement [Member]	'
Recorded Unconditional Purchase Obligation [Line Items]	'
Minimum purchase obligations, total	850,000
Operating lease obligations [Member]	'
Recorded Unconditional Purchase Obligation [Line Items]	'
Contractual Obligation, due in next twelve months	1,905,000
Contractual obligation	$6,333,000

Sale_and_Exclusive_LicenseSupp1

Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC (Details) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Jul. 30, 2013	Jun. 30, 2014
Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC [Abstract]	'	'
Aggregate value of consideration paid by Bimini	$5	'
Gain (Loss) on Sale of Business	4.5	'
Estimated future transfer and training obligations	'	215,000
Milestone payments, maximum	'	$10

Thin_Film_Japan_Distribution_A1

Thin Film Japan Distribution Agreement (Details) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 28, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2004
				Installment
Thin Film Japan Distribution Agreement [Abstract]	'	'	'	'	'	'	'
License fee recorded as deferred revenue	$2,379,000	$212,000	'	$212,000	'	$212,000	$1,500,000
Period before post commercialization in case of termination for proportional refund	'	'	'	'3 years	'	'	'
Milestone payments received	'	'	'	1,250,000	'	'	'
Payment obligation under termination agreement	'	1,200,000	'	1,200,000	'	'	'
Number of installment payments	'	'	'	6	'	'	'
Periodic payment under termination agreement	'	'	'	200,000	'	'	'
Deferred revenues	2,379,000	212,000	'	212,000	'	212,000	1,500,000
First installment payment	'	'	'	1,000,000	'	'	'
Termination fee obligation	1,200,000	200,000	'	200,000	'	'	'
Development revenue	$1,179,000	$0	$0	$0	$1,179,000	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
Assets [Abstract]	'	'
Cash equivalents	$4,644,000	$4,644,000
Level 1 [Member]	'	'
Assets [Abstract]	'	'
Cash equivalents	4,644,000	4,644,000
Level 2 [Member]	'	'
Assets [Abstract]	'	'
Cash equivalents	0	0
Level 3 [Member]	'	'
Assets [Abstract]	'	'
Cash equivalents	$0	$0

Fair_Value_Details

Fair Value (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Fixed rate long-term debt	$26,712,000	$26,207,000
Carrying Value [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Fixed rate long-term debt	26,803,000	26,241,000
Debt discount	$1,817,000	$2,379,000

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	1 Months Ended			6 Months Ended	1 Months Ended	12 Months Ended					1 Months Ended
	31-May-14	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Jan. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	31-May-14	31-May-14
	WarrantHolder			Olympus-Cytori, Inc. Joint Venture [Member]	Lazard Capital Markets, LLC [Member]	Lazard Capital Markets, LLC [Member]	Lorem Vascular [Member]	Lorem Vascular [Member]	Lorem Vascular [Member]	WBB Securities, LLC [Member]	Institutional Investors [Member]
							Closing	First Closing of Stock sale [Member]	Second Closing of Stock sale [Member]
Common Stock [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Proceeds from private placement of stock	'	'	'	'	$3,001,000	$20,007,000	$15,000,000	$12,000,000	$3,000,000	'	$10,000,000
Common stock issued (in shares)	'	'	'	'	1,053,000	7,020,000	8,000,000	4,000,000	4,000,000	'	4,048,584
Common stock at a purchase price (in dollars per unit)	'	'	'	'	'	$2.85	'	'	'	'	'
Sale of stock, price per share (in dollars per share)	'	'	'	'	'	$2.69	$3	'	'	'	$2.47
Purchase period of common stock	'	'	'	'	'	'30 days	'	'	'	'	'
Number of closings	'	'	'	'	'	'	2	'	'	'	'
Receivables from sale of stock	'	'	'	'	'	'	9,000,000	'	'	'	'
Number of warrant holders	47	'	'	'	'	'	'	'	'	'	'
Number of shares called by warrants (in shares)	3,156,238	'	'	'	'	'	'	'	'	202,429	'
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00	'	'	'	'	'	'	'	'
Exercise price of warrants (in dollars per share)	$2.62	$3.50	'	'	'	'	'	'	'	$3.09	$3
Number of holders who did not agree to Amendment	1	'	'	'	'	'	'	'	'	'	'
Number of shares called by warrants that expired unexercised (in shares)	38,500	'	'	'	'	'	'	'	'	'	'
Period in which warrants will expire	'	'	'	'	'	'	'	'	'	'	'5 years
Number of common stock available in each unit of subscription agreement (in shares)	'	'	'	'	'	'	'	'	'	'	1
Number of warrants available in each unit of subscription agreement (in shares)	'	'	'	'	'	'	'	'	'	'	1
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Royalty costs in connection with sales	'	'	'	$45,000	'	'	'	'	'	'	'